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Background: Interleukin-32 (IL-32) is an important factor in innate and adaptive immune responses, which activates
the p38MAPK, NF-kappa B and AP-1 signaling pathways. Recent reports have highlighted that IL-32 is regulated
during viral infection in humans.
Methods: Enzyme-linked immunosorbent assays (ELISA) were carried out to detect IL-32 levels in serum samples.
Detailed kinetics of the transcription of IL-32 mRNA and expression of IL-32 protein during human cytomegalovirus
(HCMV) infection were determined by semi-quantitative RT-PCR and western blot, respectively. The expression levels
of hcmv-miR-UL112-1 were detected using TaqManW miRNA assays during a time course of 96 hours. The effects of
hcmv-miR-UL112-1 on IL-32 expression were demonstrated by luciferase assay and western blot, respectively.
Results: Serum levels of IL-32 in HCMV-IgM positive patients (indicating an active HCMV infection) were
significantly higher than those in HCMV-IgM negative controls. HCMV infection activated cellular IL-32 transcription
mainly in the immediately early (IE) phase and elevated IL-32 protein levels between 6 and 72 hours post infection
(hpi) in the human embryonic lung fibroblast cell line, MRC-5. The expression of hcmv-miR-UL112-1 was detected
at 24 hpi and increased gradually as the HCMV-infection process was prolonged. In addition, it was demonstrated
that hcmv-miR-UL112-1 targets a sequence in the IL-32 30-UTR. The protein level of IL-32 in HEK293 cells could be
functionally down-regulated by transfected hcmv-miR-UL112-1.
Conclusions: IL-32 expression was induced by active HCMV infection and could be functionally down-regulated by
ectopically expressed hcmv-miR-UL112-1. Our data may indicate a new strategy of immune evasion by HCMV
through post-transcriptional regulation.
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Interleukin-32 (IL-32) is a newly-discovered pro-
inflammatory cytokine, which plays a role in innate and
adaptive immune responses [1,2]. It lacks sequence
homology to any presently known cytokine families. IL-
32 is associated with the induction of inflammatory
responses by activating the p38MAPK, NF-kappa B and
AP-1 signaling pathways. It has been implicated in in-
flammatory disorders, mycobacterium tuberculosis infec-
tions and inflammatory bowel disease, as well as in some
autoimmune diseases, such as rheumatoid arthritis,* Correspondence: ruanq@sj-hospital.org
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reproduction in any medium, provided the orulcerative colitis and Crohn’s disease [3-10]. Moreover, it
has been reported that IL-32 has pro-inflammatory effects
on myeloid cells and promotes the differentiation of
osteoclast precursors into multinucleated cells expressing
specific osteoclast markers [11,12]. In recent studies, IL-
32 has also been found to be regulated during viral infec-
tions. Elevated levels of IL-32 were found in sera from
patients infected with influenza A virus [13-15], hepatitis
B virus (HBV) [16], hepatitis C virus (HCV) [17], human
papillomavirus (HPV) [18] and human immunodeficiency
virus (HIV) [19-21], suggesting that IL-32 might play an
important role in host defense against viral infections
Human cytomegalovirus (HCMV) is an ubiquitous β-
herpesvirus that infects a broad range of cell types inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 An illustration showing IL-32 levels in serum samples
detected by ELISA. Serum samples were from actively HCMV-
infected patients (n=40), HCMV previously infected individuals
(n=17) and healthy individuals (n=15), respectively.
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pathogenesis. HCMV Infection leads to life-long per-
sistence in 50%–90% of the population, which is gen-
erally subclinical in healthy individuals [22]. However,
it can lead to serious complications in immunocomprom-
ised patients, such as transplant recipients or AIDS
patients [23,24].
MicroRNAs (miRNAs) are an abundant class of small
non-coding RNA molecules that target mRNAs generally
within their 30 untranslated regions (30UTRs). MiRNAs
suppress gene expression mainly through inhibition of
translation or, rarely, through degradation of mRNA
[25,26]. Clinical isolates of HCMV encode at least 17
miRNAs [27,28]. However, only a few functional targets
have been validated experimentally for some HCMV-
encoded miRNAs [29-34]. It has been demonstrated that
hcmv-miR-UL112-1 targets and reduces the expression
of HCMV UL123 (IE1 or IE72), UL114 and the major
histocompatibility complex class 1-related chain B
(MICB). Moreover, BclAF1 protein, a human cytomegalo-
virus restriction factor, was reported to be a new target of
hcmv-miR-UL112-1 [35]. In addition, multiple cellular
targets of hcmv-miR-US25-1, which are associated with
cell cycle control, were identified by RNA induced silen-
cing complex immunoprecipitation (RISC-IP), including
cyclin E2, BRCC3, EID1, MAPRE2 and CD147. IL-32,
which is not present in the confirmed targets, was
screened out as a candidate target of hcmv-miR-UL112-1
in our previous study [36]. However, no further experi-
ments to validate these findings have been performed.
In the present study, the expression levels of IL-32
were compared among serum samples from patients
with active HCMV infection and samples from HCMV-
IgM negative individuals. The expression levels of IL-32
and hcmv-miR-UL112-1 in HCMV infected MRC-5 cells
were detected at different stages of infection and time
points. In addition, functional down-regulation of IL-32
by hcmv-miR-UL112-1 was detected in transfected
human embryonic kidney (HEK293) cells, and the effect
of hcmv-miR-UL112-1 on IL-32 during HCMV infection
was primarily discussed.
Results
Relatively high IL-32 levels among individuals with active
HCMV infection
IL-32 protein levels were measured in the sera of 40
patients with active HCMV infections (HCMV IgM posi-
tive) and 32 HCMV IgM negative control individuals by
enzyme-linked immunosorbent assays (ELISA). Accord-
ing to the results of HCMV IgG detection, HCMV IgM
negative controls were divided into two groups: Previ-
ously HCMV infected group (IgG positive, n=17) and
healthy group (IgG negative, n=15). Mean IL-32 levels in
the sera of patients with active HCMV infection were4.1778±1.1663 ng/ml (shown in Figure 1). Mean IL-
32 levels in sera of the previously HCMV infected
group and healthy group were 2.4653±0.8287 ng/ml and
2.4480±0.9162 ng/ml, respectively. The data were analyzed
by F test. IL-32 levels in the sera of patients with active
HCMV infection were significantly higher than those in
the HCMV IgM negative control group (F=23.957,
P<0.001). No significant difference was observed between
the previously HCMV infected group and the healthy
group (P=0.963).
Kinetics of the expression of IL-32 mRNA, IL-32 protein
and hcmv-miR-UL112-1 in HCMV infected MRC-5 cells
Cells were harvested at different infection stages and
time points after HCMV infection as described in the
Materials and Methods section. We used specific drugs
to determine the expression profile of IL-32 at different
stages of viral replication. CHX was used to determine
the immediate early (IE) stage and PAA was used to de-
termine early (E) stage. As shown in Figure 2A and B,
semi-quantitative RT-PCR analysis revealed that IL-32
mRNA expression was significantly activated at IE stage
but not at E or late (L) stages post-infection. IL-32 pro-
tein expression levels at different time points following
HCMV infection were measured by western blot ana-
lysis. As shown in Figure 2C and D, IL-32 protein ex-
pression reached a peak value at 6 hours post infection
(hpi). The relative IL-32 concentration in HCMV
infected cells collected at 6 hpi was 10 fold higher than
in uninfected cells. All measured values were balanced by
using β-actin as an internal control. No accumulation of
either IL-32 mRNA or protein was found following the
prolongation of HCMV-infection process. IL-32 mRNA
levels in HCMV infected cells decreased in E and L stages
to a similar level as in uninfected cells. IL-32 protein levels
decreased with subsequent hours post infection.
In addition, the kinetics of hcmv-miR-UL112-1 expres-
sion were measured using TaqManW miRNA assays.
Figure 2 Expression of IL-32 induced by HCMV infection in MRC-5 cells. (A) IL-32 mRNA levels in HCMV infected cells were compared to
that in uninfected MRC-5 cells. β-actin was used as an internal control. The universal primers for all IL-32 transcripts were used. U is for uninfected
MRC-5; IE is for immediate early stage; E is for early stage; L is for late stage. (B) IL-32 mRNA levels were represented relative to that in IE stage.
(C) IL-32 protein levels in HCMV infected MRC-5 cells were detected at different time points. IL-32 densitometer values were normalized by β-
actin values. (D) The IL-32 protein levels were represented relative to that in infected cells collected at 6 hpi. (E) The kinetics of hcmv-miR-UL112-
1 expression were measured using TaqManW miRNA assays. The expression of hcmv-miR-UL112-1 could be detected at 24 hpi and increased
gradually as the HCMV-infection process was prolonged.
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ternal control. The expression of hcmv-miR-UL112-1
could be detected at 24 hpi. As shown in Figure 2E, a
steep increase was observed at 48 hpi. The relative quan-
tity of hcmv-miR-UL112-1 at 48 hpi was 6.5 fold higher
than at 24 hpi. The expression of hcmv-miR-UL112-1
increased gradually as the HCMV-infection process was
prolonged. The relative quantity of hcmv-miR-UL112-1
in HCMV infected cells at 96 hpi was 10 fold higher
than at 24 hpi.
Functional down-regulation of endogenous IL-32
expression by ectopically expressed hcmv-miR-UL112-1
In our previous study, a sequence in the 30UTR of IL-32
mRNA was identified by hybrid-PCR to be a candidate
target site of hcmv-miR-UL112-1. The predicted binding
site for hcmv-miR-UL112-1 was 195 nt upstream of the
polyA structure of IL-32 mRNA. A schematic represen-
tation of hcmv-miR-UL112-1 binding to the IL-32
30UTR sequence is shown in Figure 3A.To further determine whether the IL-32 30UTR
sequence represents a functional target site for hcmv-
miR-UL112-1, the IL-32 30UTR sequence was validated
by luciferase reporter assays. As shown in Figure 3B,
transfected pMIR-IL-32UTR led to a significant inhib-
ition of luciferase activity by 39.27% in the presence of
pS-miR-UL112-1. pS-miR-UL112-1 had no significant
inhibitory effects on the luciferase activities of pMIR and
pMIR-IL-32MUT. These results demonstrate that the
IL-32 30UTR sequence provided a specific and functional
binding site for hcmv-miR-UL112-1.
The regulatory effect of hcmv-miR-UL112-1 on IL-32
protein expression was then examined in HEK293 cells
by western blot. IL-32 protein level was significantly
reduced in cells transfected with hcmv-miR-UL112-1 in
comparison to cells transfected with pSilencer negative
control (Figure 3C and D). IL-32 densitometer values
were normalized to that of β-actin values. The level of re-
duction of IL-32 protein was approximately 67% as deter-
mined by densitometry (Figure 3D). Our observations
Figure 3 Down-regulation of IL-32 expression by hcmv-miR-UL112-1. (A) The diagram shows the predicted sequences of hcmv-miR-UL112-1
binding to IL-32 mRNA. (B) As a candidate target, IL-32 was validated for its ability to inhibit expression of a luciferase reporter construct in the
presence of hcmv-miR-UL112-1 (pS-miR-UL112-1). Results are shown as percentage expression of negative control sample (pS-neg) following
correction for transfection levels according to the control of renilla luciferase expression. Values are shown as means ± standard deviations for
triplicate samples. (C) HEK 293 cells were transfected with pS-miR-UL112-1 or control vector respectively. Cells were collected 48 hpi and were
subjected to western blot analysis using the indicated antibodies. IL-32 densitometer values were normalized to that of the β-actin values. (D)
The amounts of proteins presented in panel C were quantified by densitometry. Results are shown as percentage expression of the negative
control sample (Empty).
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tein could be specifically inhibited by ectopically expressed
hcmv-miR-UL112-1.
Discussion
IL-32 is a proinflammatory cytokine and plays a critical
role in inflammatory responses. It induces the expression
of IL-1β, IL-6, IL-8 and TNF through the p38MAPK,
NF-kappa B and AP-1 signaling pathways. Recent
reports have highlighted that IL-32 is regulated during
viral infection in humans. It has been reported that the
IL-32 expression could be induced during infections of
influenza A virus, HBV, HCV, HPV and HIV [13-21].
IL-32 levels, detected by ELISA, were 4.1778
±1.1663 ng/ml in sera from actively HCMV-infected
patients. IL-32 levels in sera from the previously infected
group and healthy group were 2.4653±0.8287 ng/ml and
2.4480±0.9162 ng/ml, respectively. IL-32 levels in sera
from actively HCMV-infected patients were significantly
higher than those in control groups (F=23.957, P<0.001).
However, no significant differences in IL-32 levels were
observed between the HCMV previously infected group
and healthy group (P=0.963). These results demonstrate
that IL-32 may be a newly described reactive protein
corresponding to active HCMV infection.
HCMV infection can induce the expression of IL-32 at
both the mRNA and protein levels in HCMV-infected
MRC-5 cells. The peak value of IL-32 mRNA was detected
as early as IE stage. The IL-32 protein expression levelreached peak value at 6 hpi. The IL-32 protein concentra-
tion in HCMV-infected cells at 6 hpi was 10 fold higher
than that in uninfected cells. This result demonstrated
that the production of IL-32 can be specifically induced by
active HCMV infection, while the mechanism that
induced the expression of IL-32 during HCMV infection
is still unknown. Is the induction of IL-32 mediated only
by viral entry or by the expression of IE proteins? Add-
itional experiments would be necessary to provide these
answers, and might include the use of UV-irradiated virus.
Accumulation of either IL-32 mRNA or protein was not
observed following prolonged HCMV-infection process.
IL-32 mRNA levels in HCMV-infected cells decreased
rapidly in E and L stage to a similar level to that of unin-
fected cells. IL-32 protein levels decreased in subsequent
hours post infection and could only be detected in a small
quantity by western blot at 96 hpi. It is hypothesized that
certain pathways might be activated to down-regulate or
block the expression of IL-32 during HCMV infection.
MiRNAs are the most studied non-coding RNAs in re-
cent years. They regulate gene expression at the post-
transcriptional level and act as key regulators in diverse
regulatory pathways, including early development, cell
differentiation, cell proliferation, metabolism and apop-
tosis [37-40]. We carried out additional experiments to
validate IL-32 mRNA as a target of hcmv-miR-UL112-1.
In the presence of pS-miR-UL112-1, 39.27% luciferase
activity of pMIR-IL-32UTR was observed to be signifi-
cantly decreased, and a 67% reduction of endogenous
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cells. It was confirmed that hcmv-miR-UL112-1 could
specifically repress the expression of IL-32 through the
predicted binding site.
To examine the role of hcmv-miR-UL112-1 in regulat-
ing IL-32 expression during an active HCMV infection,
the kinetics of hcmv-miR-UL112-1 expression in
HCMV-infected MRC-5 cells were measured using Taq-
ManW miRNA assays. The expression of hcmv-miR
-UL112-1 could be detected at 24 hpi and then increased
gradually with prolonged HCMV infection. This result
suggests that hcmv-miR-UL112-1 might function and
lead to the decrease of IL-32 levels in E stage during ac-
tive HCMV infection. The decrease of IL-32 mRNA, but
not IL-32 protein level, together with the dramatic in-
crease of hcmv-miR-UL112-1 during the E stage, sug-
gests the possibility that hcmv-miR-UL112-1 may
function primarily in the degradation of mRNA. Further
studies are needed to address this point.
Through co-evolution with its host, HCMV has
evolved effective immune evasion strategies by encoding
many immunomodulatory proteins that modulate the
host immune response. It is conceivable that HCMV-
encoded miRNAs might also be exploited during immune
evasion. Hcmv-miR-UL112-1 is expressed with early kin-
etics. Some functional targets of hcmv-miR-UL112-1 have
been shown experimentally to be involved in the modula-
tion of NK cell activation. Stern-Ginossar et al. have iden-
tified MICB as a functional target of hcmv-miR-UL112-1
[30]. MICB is a stress-induced ligand of the NK cell acti-
vating receptor, NKG2D, which is critical for killing of
virus-infected cells by NK cells. Hcmv-miR-UL112-1-
mediated down-regulation of MICB, perturbed MICB
binding with NKG2D and reduced killing of HCMV
infected cells by NK cells. In addition, HCMV IE1,
which would increase the TNF-α level by activation
of the TNF-α promoter, was then identified as a tar-
get of hcmv-miR-UL112-1 by Murphy et al. in 2008
[29]. It has been confirmed that IL-32 induces signifi-
cant amounts of TNF-α in a dose-dependent manner,
and that silencing endogenous IL-32 by short hairpin
RNA impairs the induction of TNF-α [2]. In this study, we
validated that expression of IL-32 was activated by active
HCMV infection and functionally down-regulated by
ectopically expressed hcmv-miR-UL112-1 in HEK293
cells. It may be deduced from these results that, besides
IE1 and MICB, hcmv-miR-UL112-1 might also synergis-
tically achieve the modulation of NK cell activation
through the TNF-α pathway by the down-regulation of
IL-32, and immune evasion by HCMV.
Conclusions
In summary, IL-32 expression in active HCMV infection
was firstly investigated in our study. Detailed kinetics ofthe transcription of hcmv-miR-UL112-1, IL-32 mRNA
and its protein expression were determined in HCMV
infected MRC-5 cells. Furthermore, IL-32 expression
was demonstrated to be functionally down-regulated by
ectopically expressed hcmv-miR-UL112-1 in HEK293
cells. Follow up studies will investigate the mechanism
of immune evasion by HCMV mediated by hcmv-miR
-UL112-1, which has been confirmed to modulate NK




Serum samples were obtained from 40 patients with
HCMV infection (22 male, 18 female, aged 2.2 ± 0.42 yr)
from Shengjing Hospital of China Medical University.
All patients were HCMV-IgM positive and HCMV-IgG
negative. The viral loads in urine samples from these
patients were between 1.793×103 and 4.115×107 HCMV
DNA copies per milliliter, as detected by routine QF-
PCR (DaAn Gene). Blood samples collected from 32
HCMV-IgM negative individuals (17 male, 15 female,
aged 2.7±0.35 yr) at the Medical Examination Centre of
Shengjing Hospital were used as controls. According to
the HCMV IgG detection results, HCMV IgM negative
controls were divided into two groups: Previously
HCMV infected group (IgG positive, n=17) and healthy
group (IgG negative, n=15). All individuals involved in
our study were seronegative for influenza A virus, HBV,
HCV and HIV. This study was specifically approved by
the Ethical Committee of Shengjing hospital.
Cell lines
HEK293 cell line was a gift of Dr. Fangjie Chen from
Department of Medical Genetics, China Medical Univer-
sity. HEK293 cells were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 100 μg/ml penicillin, 100 μg/ml
streptomycin sulfate and 2 mML-glutamine. Human
embryonic lung fibroblasts cells, MRC-5, were acquired
from Shanghai Institute for Biological Sciences, Chinese
Academy of Sciences (CAS). MRC-5 cells were main-
tained in Modified Eagle’s Medium (MEM) supplemen-
ted with 10% FBS, 100 μg/ml penicillin and 100 μg/ml
streptomycin sulfate. All cell cultures were maintained
at 37°C in a 5% CO2 incubator.
Virus
HCMV clinical strain H was isolated from a urine sam-
ple of a 5-month-old infant hospitalized in Shengjing
Hospital of China Medical University. Stock virus was
propagated in MRC-5 maintained in MEM supplemen-
ted with 2% FBS, 100 μg/ml penicillin and 100 μg/ml
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the aliquots were stored at −80°C before use.
Plasmid constructs
Luciferase reporter construct pMIR was acquired from
Ambion Company. IL-32 30UTR sequence was obtained
by RT-PCR from RNA harvested from HCMV infected
cells, and inserted into SpeI and HindIII site of the mul-
tiple cloning regions (pMIR-IL-32UTR). A point muta-
tion at corresponding seed region binding site was
maintained by using Site-directed Gene Mutagenesis Kit
(Beyotime), resulting in GUC to GAA. Sequence pre-
dicted to express hcmv-miR-UL112-1 was amplified by
PCR directly from HCMV genome. The PCR product
was inserted into BamHI and HindIII sites of pSilen-
cer4.1 (Ambion) to generate a miRNA expression vector
pS-miR-UL112-1. All primer sequences used in plasmid
construction are listed in Table 1. All constructs were
confirmed by DNA sequencing.
Enzyme-linked immunosorbent assay
The concentration of IL-32 in serum samples were
detected using human IL-32 ELISA Kit (Cusabio) accord-
ing to the manufacture’s protocols. The absorbance value
at wavelength 450 nm was measured. The IL-32 concen-
trations were calculated from the standard curve.
Semi-quantitative RT-PCR analysis
MRC-5 cells were inoculated with H strain at 3–5 multi-
plicity of infection (m.o.i.). Infections were carried out
under IE, E and L conditions respectively. For prepar-
ation of IE RNA, CHX (Sigma) (100 μl/ml) was added to
the culture medium 1 hour before infection and the cells
were harvested at 24 hpi. For E RNA, DNA synthesis in-
hibitor phosphonoacetic acid (PAA) (Sigma) (100 μl/ml)
was added to the medium immediately after infection,













Note: sequences recognized by restriction en donuclases are down lined.uninfected cellular RNA was derived from infected
(at 96 hpi) and uninfected cells, respectively. Total RNA
was isolated using Trizol reagent (TaKaRa), treated with
DNase Iand then reverse-transcribed with MLV reverse
transcriptase and random primers (TaKaRa). PCR was
performed for 24 cycles in 50 μl reactions with the IL-32
specific primer pairs listed in Table 1. mRNA of β-actin
was amplified for normalization in all reactions. The pri-
mers for IL-32 amplification were designed for detecting
all known isoforms of human IL-32 based on the
sequences from Gnebank database (NM_001012631.1-
001012636.1, NM_004221.4 and NM_001012718.1). The
PCR products were analyzed by electrophoresis on 2%
agarose gel containing ethidium bromide.
miRNA extraction and TaqMan assays
Total RNA was extracted from HCMV infected cells at
different time points using the mivVana miRNA isolation
kit (Ambion). We measured hcmv-miR-UL112-1 in all
samples using TaqManW miRNA assays (MIMAT0001577
for hcmv-miR-UL112-1, ABI). U6 expression was used to
normalize the expression of hcmv-miR-UL112-1. HCMV
uninfected MRC-5 cells were used as negative control.
Fold difference for hcmv-miR-UL112-1 expression was
calculated using the equation 2ΔΔct, where ΔCt = Ct
(hcmv-miR-UL112-1) – Ct (U6 control) and ΔΔCt = ΔCt
(HCMV infected MRC-5) – ΔCt (MRC-5). The measure-
ments were done in triplicates and the results are
presented at the means ± S.D.
Luciferase assay
MRC-5 cells were plated in 24-well plate at a density
of 4.0×105 cells per well and grown to reach about
80% confluence at the time for transfection. 200 ng pMIR-
IL-32UTR/pMIR-IL-32MUT plasmid or an empty vector
control was co-transfected with 400 ng pS-miR-UL112-1
or pS-neg control into the cells by using lipofectamine
2000 reagent (Invitrogen) according to the manufacture’s
protocol. 200 ng renilla luciferase plasmid (Promega) was
introduced into each co-transfected cells as an internal
control plasmid at the same time. Cells were collected
48 hours post transfection and luciferase activity levels
were measured using the Dual luciferase reporter assay
system (Promega) according to the manufacture’s guide-
lines. All measurements were done in triplicates and
signals were normalized for transfection efficiency to the
internal renilla control. The results are presented at the
means ±S.D.
Western blot analysis
Western blot analyses were performed to detect the IL-
32 levels in HCMV infected MRC-5 cells and hcmv-miR
-UL112-1 over expressed HEK293 cells respectively.
MRC-5 cells were inoculated with H strain at 3–5 m.o.i.
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tion (6 h, 24 h, 48 h, 72 h and 96 h). HEK293 cells were
transfected with 8 μg pS-miR-UL112-1 or pS-neg con-
trol using lipofectamine 2000 (Invitrogen) and were
incubated at 37°C for 48 hours.
Proteins of the cells described above were prepared by
suspending cells in lysis buffer, followed by centrifuga-
tion. Concentrations of proteins in supernatant were
quantified using protein assay kit (Beyotime). Protein
was separated by 10% acrylamide gel electrophoresis and
transferred onto a nitrocellulose membrane. Western
blot analysis was performed using IL-32 antibody
(abcam). Immunoblots were visualized with ECL detec-
tion system. Sample loading was normalized by quan-
tities of β-actin detected parallel.
Statistical analysis
All experiments were reproducible. The results are pre-
sented at the means ± S.D. Student’s t test and F test was
used to determine statistical significance. Differences were
considered statistically significant at value of P≤0.05.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YJH carried out the semi-quantitative RT-PCR analysis, western blot analysis
and Statistical analysis. YQ and RH carried out the plasmids construction and
luciferase assay. QR as the corresponding author designed the study and
corrected the manuscript. YPM and YHJ carried out the preparation of virus
and cell lines. ZRS carried out the serum samples collection and ELISA
detection. All authors have read and approved the final manuscript.
Acknowledgments
This work was supported by the National Natural Science Foundation of
China (81171580 and 81201274).
Received: 13 June 2012 Accepted: 28 January 2013
Published: 12 February 2013
References
1. Dinarello CA, Kim SH: IL-32, a novel cytokine with a possible role in
disease. Ann Rheum Dis 2006, 65:iii61–iii64.
2. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA: Interleukin-32: a cytokine
and inducer of TNFalpha. Immunity 2005, 22:131–142.
3. Bai X, Kim SH, Azam T, McGibney MT, Huang H, Dinarello CA, Chan ED: IL-32 is
a host protective cytokine against Mycobacterium tuberculosis in
differentiated THP-1 human macrophages. J Immunol 2010, 184(7):3830–3840.
4. Heinhuis B, Koenders MI, van de Loo FA, Netea MG, van den Berg WB, Joosten
LA: Inflammation-dependent secretion and splicing of IL-32 gamma in
rheumatoid arthritis. Proc Natl Acad Sci USA 2011, 108(12):4962–4967.
5. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR,
Barrera P, van de Loo FA, Dinarello CA, van den Berg WB: IL-32, a
proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA
2006, 103(9):3298–3303.
6. Kobayashi H, Yazlovitskaya EM, Lin PC: Interleukin-32 positively regulates
radiation-induced vascular inflammation. Int J Radiat Oncol Biol Phys 2009,
74(5):1573–1579.
7. Kundu M, Basu J: IL-32: an emerging player in the immune response
network against tuberculosis? PLoS Med 2006, 3(8):e274.
8. Netea M, Azam GT, Lewis EC, Joosten LA, Wang M, Langenberg D, Meng X,
Chan ED, Yoon DY, Ottenhoff T, Kim SH, Dinarello CA: Mycobacterium
tuberculosis induces interleukin-32 production through a caspase- 1/IL-
18/interferon-gamma-dependent mechanism. PLoS Med 2006, 3(8):e277.9. Shioya M, Nishida A, Yagi Y, Ogawa A, Tsujikawa T, Kim-Mitsuyama S, Takayanagi
A, Shimizu N, Fujiyama Y, Andoh A: Epithelial overexpression of interleukin-
32alpha in inflammatory bowel disease. Clin Exp Immunol 2007, 149(3):480–486.
10. Yagi Y, Andoh A, Imaeda H, Aomatsu T, Ohsaki R, Inatomi O, Bamba S,
Tsujikawa T, Shimizu T, Fujiyama Y: Interleukin-32α expression in human
colonic subepithelial myofibroblasts. Int J Mol Med 2011, 27(2):263–268.
11. Kim YG, Lee CK, Oh JS, Kim SH, Kim KA, Yoo B: Effect of interleukin-
32gamma on differentiation of osteoclasts from CD14+ monocytes.
Arthritis Rheum 2010, 62(2):515–523.
12. Mabilleau G, Sabokbar A: Interleukin-32 promotes osteoclast
differentiation but not osteoclast activation. PLoS One 2009, 4(1):e4173.
13. Li W, Liu Y, Mukhtar MM, Gong R, Pan Y, Rasool ST, Gao Y, Kang L, Hao Q, Peng
G, Chen Y, Chen X, Wu J, Zhu Y: Activation of interleukin-32 pro-inflammatory
pathway in response to influenza A virus infection. PLoS One 2008, 3(4):e1985.
14. Li W, Yang F, Liu Y, Gong R, Liu L, Feng Y, Hu P, Sun W, Hao Q, Kang L, Wu
J, Zhu Y: Negative feedback regulation of IL-32 production by iNOS
activation in response to dsRNA or influenza virus infection. Eur J
Immunol 2009, 39(4):1019–1024.
15. Li W, Sun W, Liu L, Yang F, Li Y, Chen Y, Fang J, Zhang W, Wu J, Zhu Y: IL-
32: a host proinflammatory factor against influenza viral replication is
upregulated by aberrant epigenetic modifications during influenza A
virus infection. J Immunol 2010, 185(9):5056–5065.
16. Pan X, Cao H, Lu J, Shu X, Xiong X, Hong X, Xu Q, Zhu H, Li G, Shen G:
Interleukin-32 expression induced by hepatitis B virus protein X is mediated
through activation of NF-κB. Mol Immunol 2011, 48(12–13):1573–1577.
17. Moschen AR, Fritz T, Clouston AD, Rebhan I, Bauhofer O, Barrie HD, Powell
EE, Kim SH, Dinarello CA, Bartenschlager R, Jonsson JR, Tilg H: Interleukin-
32: a new proinflammatory cytokine involved in hepatitis C virus-related
liver inflammation and fibrosis. Hepatology 2011, 53(6):1819–1829.
18. Lee S, Kim JH, Kim H, Kang JW, Kim SH, Yang Y, Kim J, Park J, Park S, Hong J,
Yoon DY: Activation of the interleukin-32 pro-inflammatory pathway in
response to human papillomavirus infection and over-expression of
interleukin-32 controls the expression of the human papillomavirus
oncogene. Immunology 2011, 132(3):410–420.
19. Nold MF, Nold-Petry CA, Pott GB, Zepp JA, Saavedra MT, Kim SH, Dinarello
CA: Endogenous IL-32 controls cytokine and HIV-1 production. J Immunol
2008, 181(1):557–565.
20. Rasool ST, Tang H, Wu J, Li W, Mukhtar MM, Zhang J, Mu Y, Xing HX, Wu J,
Zhu Y: Increased level of IL-32 during human immunodeficiency virus
infection suppresses HIV replication. Immunol Lett 2008, 117(2):161–167.
21. Smith AJ, Toledo CM, Wietgrefe SW, Duan L, Schacker TW, Reilly CS, Haase
AT: The immunosuppressive role of IL-32 in lymphatic tissue during HIV-
1 infection. J Immunol 2011, 186(11):6576–6584.
22. Mocarski ES, Shenk T, Pass RF: Cytomegaloviruses. In Fields Virology. 5th
edition. Edited by Knipe DM, Howley PM. Philadelphia, PA: Lippincott,
Williams & Wilkins; 2007:2701–2773.
23. Boeckh M, Zaia J: Cytomegalovirus in hematopoietic stem cell transplant
ecipients: current status, known challenges, and future strategies. Biol
Blood Marrow Transplant 2003, 9:543–558.
24. Einsele H, Hebart H: Cytomegalovirus infection following stem cell
transplantation. Haematologica 1999, 84(Suppl. EHA-4):46–49.
25. Ambros V: The functions of animal microRNAs. Nature 2003, 431:50–355.
26. Filipowicz W: RNAi: the nuts and bolts of the RISC machine. Cell 2005,
122:17–20.
27. Pfeffer S, Sewer A, Lagos-Quintana M, Sheridan R, Sander C, Grässer FA, van
Dyk LF, Ho CK, Shuman S, Chien M, Russo JJ, Ju J, Randall G, Lindenbach
BD, Rice CM, Simon V, Ho DD, Zavolan M, Tuschl T: Identification of
microRNAs of the herpesvirus family. Nat Methods 2005, 2(4):269–276.
28. Dunn W, Trang P, Zhong Q, Yang E, van Belle C, Liu F: Human
cytomegalovirus expresses novel microRNAs during productive viral
infection. Cell Microbiol 2005, 7(11):1684–1695.
29. Grey F, Meyers H, White EA, Spector DH, Nelson J: A human
cytomegalovirus-encoded microRNA regulates expression of multiple
viral genes involved in replication. PLoS Pathog 2007, 3(11):e163.
30. Stern-Ginossar N, Elefant N, Zimmermann A, Wolf DG, Saleh N, Biton M,
Horwitz E, Prokocimer Z, Prichard M, Hahn G, Goldman-Wohl D, Greenfield
C, Yagel S, Hengel H, Altuvia Y, Margalit H, Mandelboim O: Host immune
system gene targeting by a viral miRNA. Science 2007, 317(5836):376–381.
31. Murphy E, Jiří V, Thomas S, Arnold JL: Suppression of immediate-early viral
gene expression by herpesvirus-coded microRNAs: Implications for
latency. Proc Natl Acad Sci USA 2008, 105(14):5453–5458.
Huang et al. Virology Journal 2013, 10:51 Page 8 of 8
http://www.virologyj.com/content/10/1/5132. Stern-Ginossar N, Saleh N, Goldberg MD, Prichard M, Wolf DG, Mandelboim
O: Analysis of human cytomegalovirus-encoded microRNA activity
during infection. J Virol 2009, 83(20):10684–10693.
33. Grey F, Tirabassi R, Meyers H, Wu G, McWeeney S, Hook L, Nelson JA: A viral
microRNA down-regulates multiple cell cycle genes through mRNA
50UTRs. PLoS Pathog 2010, 6(6):e1000967.
34. Kim S, Lee S, Shin J, Kim Y, Evnouchidou I, Kim D, Kim YK, Kim YE, Ahn JH,
Riddell SR, Stratikos E, Kim VN, Ahn K: Human cytomegalovirus microRNA
miR-US4-1 inhibits CD8(+) T cell responses by targeting the
aminopeptidase ERAP1. Nat Immunol 2011, 12(10):984–991.
35. Lee SH, Kalejta RF, Kerry J, Semmes OJ, O’Connor CM, Khan Z, Garcia BA,
Shenk T, Murphy E: BclAF1 restriction factor is neutralized by proteasomal
degradation and microRNA repression during human cytomegalovirus
infection. Proc Natl Acad Sci USA 2012, 109(24):9575–9580.
36. Huang Y, Qi Y, Ruan Q, Ma Y, He R, Ji YH, Sun ZR: A rapid method to
screen putative mRNA targets of any known microRNA. Virol J 2011, 8:8.
37. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz
HR, Ruvkun G: The 21-nucleotide let-7 RNA regulates developmental timing
in Caenorhabditis elegans. Nature 2000, 403:901–906.
38. Brennecke J, Hipfner DR, Stark A, Russel RB, Cohen SM: Bantam encodes a
developmentally regulated microRNA that controls cell proliferation and
regulates the proapoptotic gene hid in Drosophila. Cell 2003, 113:25–36.
39. Dostie J, Mourelatos Z, Yang M, Sharma A, Dreyfuss G: Numerous
microRNPs in neuronal cells containing novel microRNAs. RNA 2003,
9:180–186.
40. Xu P, Vernooy SY, Guo M, Hay BA: The Drosophila microRNA Mir-14
suppresses cell death and is required for normal fat metabolism.
Curr Biol 2003, 13:790–795.
doi:10.1186/1743-422X-10-51
Cite this article as: Huang et al.: The expression of interleukin-32 is
activated by human cytomegalovirus infection and down regulated by
hcmv-miR-UL112-1. Virology Journal 2013 10:51.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
